Business Express is an online portal that covers the latest developments in the world of business and finance. From startups and entrepreneurship to mergers and acquisitions, Business Express provides reporting on the stories that matter most to business leaders and decision-makers.The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
2024 02 27T064658Z 1 LYNXNPEK1Q04J RTROPTP 4 STRAUMANN RESULTS scaled - Business Express

Dental implants maker Straumann sees steady sales growth in 2024

Dental implants maker Straumann sees steady sales growth in 2024

(Reuters) – Swiss dental implant maker Straumann on Tuesday forecast 2024 sales growth at a similar level to last year’s, taking a cautious stance amidst prolonged economic uncertainty.

“While geopolitical and macroeconomic uncertainties are going to continue to impact consumer confidence in different geographies, the overall patient flow is expected to keep a positive dynamic,” CEO Guillaume Daniellot said in a statement.

The group, which specialises in tooth replacement and orthodontic solutions, expects its organic revenue to grow in a high single-digit percentage this year, while the margin on earnings before interest and taxes should be around 26% at constant currency rates.

Analysts polled by LSEG were expecting sales to grow by 8.2%, and an EBIT margin of 24.9% in 2024.

For last year, Straumann reported 9.8% organic revenue growth to 2.4 billion Swiss francs ($2.7 billion) and an operating profit margin of 25.1%.

That was in line with analysts’ expectations even as strong Swiss franc against U.S. dollar hit Straumann which makes most of its earnings outside of Switzerland.

During the fourth quarter, the group’s Asia-Pacific sales grew by 40%, boosted by the Chinese government’s value-based procurement plan — a tender programme for healthcare products aimed at lowering costs for consumers.

Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!

By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.

Sales grew by 7.2% in North America and by 5.8% in Europe, Middle East and Africa (EMEA).

While North American results were subdued due to consumer weakness, Europe showed steady patient flow growth, the company said.

Straumann will propose an increased dividend of 0.85 francs per share for 2023, versus 0.8 francs last year.

($1 = 0.8796 Swiss francs)


(Reporting by Andrey Sychev and Marleen Kaesebier in Gdansk; editing by Milla Nissi)


Recent Post: